Thu, Jul 10, 2014, 2:23 PM EDT - U.S. Markets close in 1 hr 37 mins

Recent

% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • tomorrowyesterdaystoday tomorrowyesterdaystoday Aug 9, 2013 8:54 AM Flag

    Investors just don't have patience

    Real wealth is the transfer $$$ to those who have patience from those who don't.
    I wouldn't sweat it. Let it fall and buy more. It's like taking candy from a baby. The AMGN withfdrawl is a positive in my mind, should help ARRY focus on what's important and the headcount cut saves cash. I liked it; and I'm liking it more when I see the stock fall like this. Buying opp soon, but let a few more lemmings sell first.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I have all the patience in the world, the potential this co has is beyond belief , if you really believe put your shares away and you see triple digits within 4 years

    • There is almost no way I conceive that the AMGN news is good news. Almost certainly the drug is not worth advancing. That's bad. It's good that they reacted instantly to the news to control costs. That's very good. I felt good about management and this makes me feel better.

      I suppose there is some wild #$%$ chance that they have a deal going somehow that AMGN doesn't like but if this drug was really good they would have kept it. They didn't. Frankly I am surprised its holding up as well as it has. I haven't sold any.

      I see Merrimack is back chirping. Pay no attention. It's last call was to sell at $3.60 and go long at $2 or something like that. Put it on ignore. Has no credibility.

    • Traders make money here. Investors should have brought JSDA last year. Sugar water sold as soda is better than sugar pawned off as a drug placebo by ARRY.

 
ARRY
4.115+0.015(+0.37%)2:22 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.